EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE Drug Patent Profile
✉ Email this page to a colleague
When do Emtricitabine And Tenofovir Disoproxil Fumarate patents expire, and when can generic versions of Emtricitabine And Tenofovir Disoproxil Fumarate launch?
Emtricitabine And Tenofovir Disoproxil Fumarate is a drug marketed by Hetero Labs Ltd Iii and is included in one NDA.
The generic ingredient in EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is emtricitabine; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Emtricitabine And Tenofovir Disoproxil Fumarate
A generic version of EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE was approved as emtricitabine; tenofovir disoproxil fumarate by TEVA PHARMS USA on June 8th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE?
- What are the global sales for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE?
- What is Average Wholesale Price for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE?
Summary for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 179 |
DailyMed Link: | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE at DailyMed |
Recent Clinical Trials for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University College, London | Phase 3 |
King's College London | Phase 3 |
Africa Health Research Institute | Phase 3 |
See all EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE clinical trials
Pharmacology for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
US Patents and Regulatory Information for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hetero Labs Ltd Iii | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 201806-001 | Oct 7, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |